| 名稱 | KIF5B（E15）-RET（E12）-Short/BaF3 |
| 型號(hào) | CBP73205 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | KIF5B（E15）-RET（E12）-Short/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 新加坡科學(xué)家找到治療侵襲性卵巢癌的新可能
- GARP/LTGF-β細(xì)胞模型簡介
- 【新品上線】TIM-3細(xì)胞篩選模型
- 新品發(fā)布【地中海貧血標(biāo)準(zhǔn)品】
- ATCC細(xì)胞株培養(yǎng)操作
- 從諾輝財(cái)報(bào)看甲基化市場，科佰生物助力甲基化標(biāo)準(zhǔn)品的開發(fā)
- 肥胖與腫瘤治療新星靶點(diǎn)——GDF15-GFRAL
- 腫瘤細(xì)胞上的DNA排列方式探討
- 子宮內(nèi)膜癌精準(zhǔn)分子分型標(biāo)準(zhǔn)品，助力POLE基因檢測
- DPCR檢測試劑盒開發(fā)性能驗(yàn)證
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73205KIF5B（E15）-RET（E12）-Short/BaF3
- 詳細(xì)內(nèi)容
| CBP73205 | |
| I. Introduction | |
Cell Line Name： | KIF5B(E15)-RET(E12)-Short/BaF3 |
Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+1 ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies. | |
| III. Representative Data | |
1. WB of KIF5B-RET (K15, R12S)/BaF3
| |
2. Sanger of KIF5B-RET (K15, R12S)/BaF3
| |
3. Anti-proliferation assay
Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (s) Cells (C6). | |
會(huì)員_a.png)